Bayer, Orion prostate cancer drug delays spread of disease in PhIII, but can it make a mark in a crowded market?
Bayer and Finland’s Orion (ORNBV: $FH) on Wednesday said their prostate cancer drug, darolutamide, met the main goal in a late-stage trial, lifting Orion’s shares up in Helsinki by nearly 10%. But the two drugmakers may be late to the party, with other such androgen receptor (AR) inhibitors such as Pfizer’s $PFE Xtandi as well as J&J’s $JNJ newer Erleada already on the market.
The trial tested darolutamide against a placebo in more than 1,500 patients with non-metastatic castration-resistant prostate cancer (nmCRPC) that were already on standard-of-care androgen deprivation therapy, and were at risk of the disease spreading. Data showed the drug met the primary endpoint of metastasis-free survival, as it thwarted the cancer from spreading over the course of the study. Detailed results will be presented at an upcoming scientific meeting, the companies said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.